Compare Quest Diagnostics Inc (DGX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.75B). The key difference: Quest Diagnostics Inc is far larger — about 14.6× VanEck Rare Earth/Strategic Metals's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| DGX | REMX | |
|---|---|---|
Market Cap | $25.48B | $1.75B |
Volume | 941,866 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $109.53 |
52-Week Low | $173.49 | $60.58 |
Typical Hold Time | 56 Days | 50 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.58, down 2.1% with a bearish technical outlook. The ETF shows high volatility and faces pressure from rare earth market dynamics. Recent news highlights geopolitical tensions around critical minerals and China's export controls, while institutional interest includes Bank of America increasing its stake by 72.1% in Q2 2026 (SEC filing, August 2026).
Outlook remains cautious due to sector volatility and China dependency risks. Investment appeal lies in strategic positioning for supply chain independence, but high turnover and exposure fluctuations warrant careful risk assessment. Key catalysts include U.S. policy developments and rare earth supply chain expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
